인공수정 시장 보고서 : 유형별, 유래 유형별, 최종 용도별, 지역별(2025-2033년)

The global artificial insemination market size reached USD 2.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 4.6 Billion by 2033, exhibiting a growth rate (CAGR) of 7.15% during 2025-2033. North America represents the largest region owing to the heightened awareness about the advantages of artificial insemination, the rising consumer per capita expenditure, and increasing healthcare expenditure. Moreover, increasing infertility rates, rapid lifestyle changes, and escalating prevalence of medical conditions represent some of the key factors driving the market demand.

The artificial insemination industry is facing tremendous changes driven by a cocktail of technological innovation, shifts in people's behavior, and increasing uses in various industries. The increasing use of data analytics in artificial insemination is one of the major trends transforming the market. Both in human fertility and in the livestock breeding industry, data analytics is being utilized to improve the efficiency and accuracy of artificial insemination procedures. In human fertility, clinics are now using big data and artificial intelligence (AI) algorithms to identify the optimal times for insemination, enhance sperm and egg selection, and maximize embryo culture environments. By using this data, fertility doctors can provide individualized treatment options tailored to the patient's unique requirements, thus increasing the possibilities of successful pregnancy. Machine learning (ML) and AI computer algorithms are also being utilized to sort through large data sets, which assist in further understanding infertility patterns and enhanced clinical outcomes.

Artificial Insemination Market Trends:

Technological Advancements in Artificial Insemination

Technological innovation is largely propelling the artificial insemination market through enhanced efficiency, success rates, and accessibility of artificial insemination procedures. In human fertility therapy, technological advancements in sperm selection, embryo culture, and cryopreservation are augmenting the accuracy and efficacy of artificial insemination. Methods like genetic screening and embryo grading are increasingly becoming sophisticated, translating to improved results for patients receiving artificial insemination-based reproductive therapies. For instance, the Ministry of Health and Prevention (MoHAP) announced that compulsory genetic testing will be implemented as part of the premarital screening program for all Emiratis intending to marry across the country, beginning in early January 2025. Moreover, in livestock breeding, the advancement of technology in semen freezing and storage is enabling improved preservation and longer utilization of quality semen. On-farm artificial insemination and automation are further enhancing the effectiveness of artificial insemination processes in agriculture to allow farmers to conduct insemination with reduced intervention.

Growing Usage of Artificial Insemination in Livestock Breeding

Growing usage of artificial insemination in animal breeding is significantly contributing to the growth of the market. Livestock farmers are increasingly using artificial insemination to enhance the quality of their herds, particularly in cattle, pigs, and poultry. Artificial insemination is helping farmers to selectively breed animals with superior characteristics like resistance to diseases, increased milk output, and quality meat, leading to enhanced productivity and profitability. This adoption is driven by increasing demand for quality meat and dairy because consumers are becoming concerned about the quality of food. Artificial insemination is also offering an answer for improving the herd genetics and handling the issue of inbreeding, especially in the livestock with low levels of genetic diversity. In 2025, the Union Cabinet sanctioned the Revised Rashtriya Gokul Mission (RGM) to enhance development in the livestock industry. The updated mission will be executed as a Central Sector part of the Development Programmes initiative, with an added expenditure of ₹1,000 crore, raising the overall funding to ₹3,400 crore for the 15th Finance Commission period from 2021-22 to 2025-26. The program will maintain its primary functions, which involve enhancing semen stations and artificial insemination networks, executing bull production and expedited breed enhancement programs with sex-sorted semen, promoting skill development and farmer education efforts, and creating Centres of Excellence while bolstering Central Cattle Breeding Farms.

Growing Fertility Treatment Demand

Growing demand for fertility treatments is one of the primary drivers of the artificial insemination sector, specifically in human reproductive medicine. The 2025 State of World Population (SOWP) Report from the United Nations Population Fund (UNFPA), named 'The Real Fertility Crisis', indicates that one in three adult Indians (36%) encounters unintended pregnancies, and 30% have unfulfilled wishes for having either more or fewer children. As societal attitudes change, most people and couples are opting to postpone childbearing because of personal or work-related issues, thus contributing to the rise in infertility cases. This transformation is driving the demand for assisted reproductive technologies (ART), such as artificial insemination. The increasing incidence of infertility, frequently associated with lifestyle factors, medical conditions, and environmental contaminants, is further stimulating the demand for fertility treatments. With increased interest in overcoming fertility issues, artificial insemination is increasingly proving to be a key solution because it is non-invasive and has high success rates.

Artificial Insemination Market Growth Drivers:

Government Policies and Support

Government assistance is contributing to the market growth by implementing various policies and programs that promote the use of artificial insemination technologies, mainly in agriculture and the health sector. In the agricultural sector, numerous governments are providing subsidies, monetary incentives, and grants to promote the use of artificial insemination in breeding. Such policies are enabling farmers to avail themselves of sophisticated reproductive technologies that would otherwise be too expensive for them. Also, governments are making investments in infrastructure to develop, for example artificial insemination artificial insemination training facilities for farmers and veterinary experts to ensure the presence of a skilled workforce to facilitate the adoption of artificial insemination. In the field of human fertility, governments are increasingly offering subsidies to fertility clinics, regulating artificial insemination-reliant reproductive technologies, and providing financial aid or insuring fertility treatments.

Social Acceptance and Cultural Shifts

Social acceptance and cultural shifts in attitudes toward family planning and fertility treatments are driving the demand for artificial insemination. With changing societal values, more people and couples are setting career aspirations, higher education, and self-improvement as top priorities, resulting in postponing marriage and having children. These trends are translating into increased use of fertility treatments, such as artificial insemination, as people are preferring to avoid natural conception later in life. The stigma regarding infertility and assisted reproductive technology is also slowly fading as people increasingly talk about their fertility issues and choose artificial insemination-based approaches. This change in the social attitudes is making artificial insemination a more accepted way to conceive. In the same way, artificial insemination is changing the face of livestock farming, becoming a mainstream technology with farmers welcoming its ability to enhance animal genetics, maximize efficiency, and minimize the carbon footprint.

Economic Benefits and Cost-Effectiveness

Economic conditions are becoming the driving force behind the artificial insemination industry, especially within livestock breeding. With the expense of traditional breeding techniques, for example, keeping extensive herds of bulls or incurring costs for natural mating, on the increase, artificial insemination is becoming a cost-cutting solution. Artificial insemination enables farmers to utilize quality genetics from leading bulls with no need for heavy infrastructure, keeping breeding expenses down to a fraction. This affordability is assisting farmers, particularly in developing countries, in enhancing the profitability and productivity of their farms. In the same way, in the market for human fertility, the affordability of artificial insemination over other assisted reproductive technologies, is making it a viable choice for most people.

Global Artificial Insemination Industry Segmentation:

Breakup by Type:

• Intrauterine
• Intracervical
• Intravaginal
• Intratubal

The intrauterine segment dominates the market

According to the artificial insemination market outlook, intrauterine insemination involves placing sperm directly into the uterus, increasing the chances of sperm reaching the egg for fertilization. IUI generally offers higher success rates, particularly when dealing with male infertility factors such as low sperm motility. This makes it a preferred option for many patients.

Breakup by Source Type:

• AIH-Husband
• AID-Donor

According to the artificial insemination market outlook report, AIH involves using the husband's (or male partner's) sperm for insemination, often after sperm preparation to optimize chances of fertilization. One of the primary drivers of AIH is male factor infertility, which can involve low sperm count, poor sperm motility, or abnormal sperm morphology. AIH is often used when the sperm is viable but needs to be concentrated or processed for better chances of fertilization. Moreover, AID involves using donor sperm, typically from a sperm bank, to inseminate the woman. This is often done when the male partner's sperm is not viable or in cases where the woman is single or in a same-sex relationship.

Breakup by End Use:

• Hospitals and Clinics
• Fertility Centers
• Others

The fertility centers segment spearheads the market

According to the artificial insemination market forecast report, the demand for Artificial Insemination (AI) in fertility centers is driven by a combination of medical, technological, demographic, and social factors. Fertility centers play a critical role in providing specialized reproductive services, and they are at the forefront of delivering assisted reproductive technologies (ART) such as intrauterine insemination (IUI), intracervical insemination (ICI), and other AI procedures.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America dominates the market

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America dominates the market.

According to the artificial insemination market statistics, some of the factors accelerating the North America artificial insemination market include the surging awareness regarding the advantages of artificial insemination, the rising consumer per capita expenditure, and burgeoning healthcare expenditure. The rising infertility rates among both men and women, driven by lifestyle changes, stress, pollution, delayed childbearing, and certain medical conditions, are a major driver of the AI market. Infertility rates have steadily increased in the region, with many couples and individuals turning to artificial insemination as a solution. Moreover, in North America, many women are choosing to delay parenthood due to career, financial, or personal reasons. For instance, according to an article published by Forbes, over the last decade, as more women of all social groups have emphasized education and profession, deferring motherhood has become practically universal among American women. As maternal age increases, fertility declines, leading to more individuals seeking assisted reproductive technologies (ART), including artificial insemination, to conceive. According to the artificial insemination market research, this is augmenting the regional market.

Competitive Landscape:

The artificial insemination market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include:

• Conceivex Inc.
• FUJIFILM Irvine Scientific Inc. (Fujifilm Holdings Corporation)
• Genea Limited
• Genus plc
• Hamilton Thorne Inc.
• Hi-Tech Solutions
• Kitazato Corporation
• Pride Angel
• Rinovum Women's Health LLC
• Rocket Medical plc
• TenderNeeds Fertility LLC
• Vitrolife AB

Key Questions Answered in This Report

• 1.How big is the global artificial insemination market?
• 2.What is the expected growth rate of the global artificial insemination market during 2025-2033?
• 3.What are the key factors driving the global artificial insemination market?
• 4.What has been the impact of COVID-19 on the global artificial insemination market?
• 5.What is the breakup of the global artificial insemination market based on the type?
• 6.What is the breakup of the global artificial insemination market based on the end use?
• 7.What are the key regions in the global artificial insemination market?
• 8.Who are the key players/companies in the global artificial insemination market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Artificial Insemination Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Intrauterine
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Intracervical
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Intravaginal
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Intratubal
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by Source Type

• 7.1 AIH-Husband
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 AID-Donor
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by End Use

• 8.1 Hospitals and Clinics
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Fertility Centers
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Others
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Conceivex Inc.
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
  • 14.3.2 FUJIFILM Irvine Scientific Inc. (Fujifilm Holdings Corporation)
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
  • 14.3.3 Genea Limited
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
  • 14.3.4 Genus plc
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 Hamilton Thorne Inc.
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
  • 14.3.6 Hi-Tech Solutions
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
  • 14.3.7 Kitazato Corporation
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
  • 14.3.8 Pride Angel
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
  • 14.3.9 Rinovum Women's Health LLC
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
  • 14.3.10 Rocket Medical plc
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
  • 14.3.11 TenderNeeds Fertility LLC
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
  • 14.3.12 Vitrolife AB
    • 14.3.12.1 Company Overview
    • 14.3.12.2 Product Portfolio
    • 14.3.12.3 Financials